AR040068A1 - Inhibidores de la adhesion celular mediada por integrina alpha l beta 2 - Google Patents

Inhibidores de la adhesion celular mediada por integrina alpha l beta 2

Info

Publication number
AR040068A1
AR040068A1 ARP030100379A ARP030100379A AR040068A1 AR 040068 A1 AR040068 A1 AR 040068A1 AR P030100379 A ARP030100379 A AR P030100379A AR P030100379 A ARP030100379 A AR P030100379A AR 040068 A1 AR040068 A1 AR 040068A1
Authority
AR
Argentina
Prior art keywords
integrina
inhibitors
beta
alpha
cellular adhesion
Prior art date
Application number
ARP030100379A
Other languages
English (en)
Spanish (es)
Inventor
Ila Sircar
Marshall Morningstar
Masatoshi Kakushima
Hidefumi Kaji
Takayuki Kawaguchi
Toshiyuki Kume
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR040068A1 publication Critical patent/AR040068A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
ARP030100379A 2002-02-07 2003-02-06 Inhibidores de la adhesion celular mediada por integrina alpha l beta 2 AR040068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07

Publications (1)

Publication Number Publication Date
AR040068A1 true AR040068A1 (es) 2005-03-16

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100379A AR040068A1 (es) 2002-02-07 2003-02-06 Inhibidores de la adhesion celular mediada por integrina alpha l beta 2

Country Status (23)

Country Link
US (1) US7375128B2 (cg-RX-API-DMAC7.html)
EP (1) EP1472257B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005517016A (cg-RX-API-DMAC7.html)
KR (1) KR100625379B1 (cg-RX-API-DMAC7.html)
CN (1) CN1301255C (cg-RX-API-DMAC7.html)
AR (1) AR040068A1 (cg-RX-API-DMAC7.html)
AT (1) ATE411995T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003210862B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307521A (cg-RX-API-DMAC7.html)
CA (1) CA2474748A1 (cg-RX-API-DMAC7.html)
CO (1) CO5601028A2 (cg-RX-API-DMAC7.html)
DE (1) DE60324250D1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045222A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007643A (cg-RX-API-DMAC7.html)
MY (1) MY137878A (cg-RX-API-DMAC7.html)
NO (1) NO20043563L (cg-RX-API-DMAC7.html)
NZ (1) NZ534208A (cg-RX-API-DMAC7.html)
PE (1) PE20030899A1 (cg-RX-API-DMAC7.html)
PL (1) PL372328A1 (cg-RX-API-DMAC7.html)
RU (1) RU2315768C2 (cg-RX-API-DMAC7.html)
TW (1) TW200303200A (cg-RX-API-DMAC7.html)
WO (1) WO2003066636A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405647B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
PE20070707A1 (es) * 2005-10-06 2007-08-20 Novartis Ag Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066B1 (en) * 2019-05-16 2025-08-20 Dispensing Dynamics International, Inc. Fragrance dispenser

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
US6214834B1 (en) * 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
WO1998058947A1 (en) 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
NZ518369A (en) 1999-10-20 2003-09-26 Tanabe Seiyaku Co 1,3 or 1,8-Diazabicyclo octane or nonane derivatives or tricyclic derivatives useful as inhibitors of alphaL-beta2 mediated cell adhesion
AU6489201A (en) * 2000-05-23 2001-12-03 Histatek Llc Modulaton of alpha-6 integrin-mediated responses

Also Published As

Publication number Publication date
PE20030899A1 (es) 2003-10-25
AU2003210862A1 (en) 2003-09-02
BR0307521A (pt) 2004-12-28
AU2003210862B2 (en) 2006-10-26
MXPA04007643A (es) 2005-06-08
DE60324250D1 (de) 2008-12-04
KR20040091625A (ko) 2004-10-28
MY137878A (en) 2009-03-31
CN1301255C (zh) 2007-02-21
NZ534208A (en) 2005-12-23
CO5601028A2 (es) 2006-01-31
NO20043563L (no) 2004-11-01
CA2474748A1 (en) 2003-08-14
WO2003066636A1 (en) 2003-08-14
EP1472257B1 (en) 2008-10-22
TW200303200A (en) 2003-09-01
US20050171174A1 (en) 2005-08-04
PL372328A1 (en) 2005-07-11
US7375128B2 (en) 2008-05-20
RU2004123219A (ru) 2006-02-10
KR100625379B1 (ko) 2006-09-20
RU2315768C2 (ru) 2008-01-27
ZA200405647B (en) 2005-07-15
CN1628116A (zh) 2005-06-15
JP2005517016A (ja) 2005-06-09
EP1472257A1 (en) 2004-11-03
ATE411995T1 (de) 2008-11-15
ECSP045222A (es) 2006-04-19

Similar Documents

Publication Publication Date Title
MEP13008A (en) C-aryl glucoside sglt2 inhibitors and method
PT1307455E (pt) Inibidores de adesao celular mediada por (alfa)l (beta)2
FI1610780T4 (fi) Sykliset proteiinityrosiinikinaasi-inhibiittorit
TW200730540A (en) Novel peptide compounds
AR040068A1 (es) Inhibidores de la adhesion celular mediada por integrina alpha l beta 2
EP2374464A3 (en) HCV N3S-NS4A protease inhibition
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
TW200505919A (en) DPP-IV inhibitors
DK1565471T3 (da) Quionolinylpyrazoler
EA011572B9 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
DE602005016297D1 (de) Antithrombotische diamide
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
SE0302323D0 (sv) Novel compounds
TW200633979A (en) Method
MX2007003913A (es) Alquil-piridinas como inhibidores de 11 beta para diabetes.
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
UY28688A1 (es) Derivados de amida
WO2006008545A3 (en) Thiazole and isothiazole derivatives as protein kinase inhibitors
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
TW200505869A (en) Thiophenylaminoimidazolines
CO5540310A2 (es) Derivados de tri- y tetraazaacenaftileno como antagonista del receptor de crf
DE602004009664D1 (de) Diclazurilhaltige antiprotozoenmittel
PE20040903A1 (es) Derivados de nucleosido antivirales

Legal Events

Date Code Title Description
FB Suspension of granting procedure